StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Iovance Biotherapeutics total assets

Total assets on the balance sheet at the end of each period.

Iovance Biotherapeutics's total assets was $915.53M at Jun 30, 2026. For fiscal 2025 it was $913.17M, up 0.3% from the year before. Over ten years it grew 24.1% a year on average. The highest annual figure on record is $913.17M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$913.17M+0.3%
FY2024Dec 31, 2024$910.43M+16.7%
FY2023Dec 31, 2023$780.35M+17.5%
FY2022Dec 31, 2022$663.98M-14.6%
FY2021Dec 31, 2021$777.33M+1.2%
FY2020Dec 31, 2020$768.46M+123.0%
FY2019Dec 31, 2019$344.66M-28.3%
FY2018Dec 31, 2018$480.82M+209.5%
FY2017Dec 31, 2017$155.37M-9.6%
FY2016Dec 31, 2016$171.89M+62.7%
FY2015Dec 31, 2015$105.65M+127.2%
FY2014Dec 31, 2014$46.51M+134.0%
FY2013Dec 31, 2013$19.87M+67467.6%
FY2012Dec 31, 2012$29.41K-94.8%
FY2011Dec 31, 2011$568.43K-61.1%
FY2010Dec 31, 2010$1.46M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$915.53M+0.9%
Q1 FY2026Mar 31, 2026$925.67M-4.2%
Q4 FY2025Dec 31, 2025$913.17M+0.3%
Q3 FY2025Sep 30, 2025$904.95M-8.7%
Q2 FY2025Jun 30, 2025$907.44M-5.9%
Q1 FY2025Mar 31, 2025$966.74M+11.1%
Q4 FY2024Dec 31, 2024$910.43M+16.7%
Q3 FY2024Sep 30, 2024$991.12M+16.3%
Q2 FY2024Jun 30, 2024$964.32M+27.3%
Q1 FY2024Mar 31, 2024$869.83M+5.5%
Q4 FY2023Dec 31, 2023$780.35M+17.5%
Q3 FY2023Sep 30, 2023$852.32M+56.1%
Q2 FY2023Jun 30, 2023$757.29M+24.0%
Q1 FY2023Mar 31, 2023$824.77M+17.6%
Q4 FY2022Dec 31, 2022$663.98M-14.6%
Q3 FY2022Sep 30, 2022$545.92M-34.1%
Q2 FY2022Jun 30, 2022$610.88M-28.4%
Q1 FY2022Mar 31, 2022$701.25M-6.6%
Q4 FY2021Dec 31, 2021$777.33M+1.2%
Q3 FY2021Sep 30, 2021$828.83M+5.9%
Q2 FY2021Jun 30, 2021$852.79M+4.3%
Q1 FY2021Mar 31, 2021$750.57M+160.3%
Q4 FY2020Dec 31, 2020$768.46M+123.0%
Q3 FY2020Sep 30, 2020$782.29M+97.7%
Q2 FY2020Jun 30, 2020$817.57M+87.5%
Q1 FY2020Mar 31, 2020$288.30M-37.5%
Q4 FY2019Dec 31, 2019$344.66M-28.3%
Q3 FY2019Sep 30, 2019$395.75M+46.1%
Q2 FY2019Jun 30, 2019$435.92M+53.1%
Q1 FY2019Mar 31, 2019$461.50M+50.2%
Q4 FY2018Dec 31, 2018$480.82M+209.5%
Q3 FY2018Sep 30, 2018$270.83M+55.7%
Q2 FY2018Jun 30, 2018$284.75M+106.3%
Q1 FY2018Mar 31, 2018$307.25M+97.7%
Q4 FY2017Dec 31, 2017$155.37M-9.6%
Q3 FY2017Sep 30, 2017$173.97M-4.6%
Q2 FY2017Jun 30, 2017$138.01M–
Q1 FY2017Mar 31, 2017$155.39M–
Q4 FY2016Dec 31, 2016$171.89M–
Q3 FY2016Sep 30, 2016$182.33M–

More Iovance Biotherapeutics figures

See a number that looks wrong?